Mycophenolate mofetil (MMF) showed no clear difference in death, all cause compared with azathioprine (AZA) (moderate certainty).
Mycophenolate mofetil (MMF) leads to lower graft loss, censored for death compared with azathioprine (AZA) (high certainty).
It is very uncertain whether mycophenolate mofetil (MMF) changes malignancy, any compared with azathioprine (AZA) (very low certainty).
Mycophenolate mofetil (MMF) leads to lower acute rejection, steroid resistant/antibody treated As reported in… compared with azathioprine (AZA) (high certainty).
Mycophenolate mofetil (MMF) leads to higher infection, CMV tissue invasive As reported in the articles compared with azathioprine (AZA) (high certainty).
Mycophenolate mofetil (MMF) leads to lower acute rejection, total Any treated acute rejection, including… compared with azathioprine (AZA) (high certainty).
Mycophenolate mofetil (MMF) may leads to lower chronic allograft nephropathy Biopsy required in 2 RCTs, one study… compared with azathioprine (AZA) (low certainty).
Mycophenolate mofetil (MMF) + tacrolimus (TAC) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).
Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher stable kidney function compared with IV cyclophosphamide (CPA) (low certainty).
Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher complete renal remission compared with IV cyclophosphamide (CPA) (low certainty).
Cyclosporin showed no clear difference in treatment response at 52 weeks: complete remission (primary outcome… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
Cyclosporin showed no clear difference in treatment response at 52 weeks: partial remission (primary outcome 3) compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
Cyclosporin showed no clear difference in sustainable remission between 52 and 78 weeks: complete or partial… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
Cyclosporin showed no clear difference in CKD or death: death by 52 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
Cyclosporin showed no clear difference in CKD or death: 50% decline in GFR by 78 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): hypertension compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
Tacrolimus may leads to higher number with complete or partial response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
Tacrolimus may leads to higher number with complete response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
Tacrolimus showed no clear difference in number with partial response at one year compared with mycophenolate mofetil to maintain remission (low certainty).